CN113185602B - 获得肿瘤特异性t细胞受体的方法 - Google Patents

获得肿瘤特异性t细胞受体的方法 Download PDF

Info

Publication number
CN113185602B
CN113185602B CN202110295872.5A CN202110295872A CN113185602B CN 113185602 B CN113185602 B CN 113185602B CN 202110295872 A CN202110295872 A CN 202110295872A CN 113185602 B CN113185602 B CN 113185602B
Authority
CN
China
Prior art keywords
population
tumor antigen
cells
loaded
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110295872.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113185602A (zh
Inventor
周向军
韩研妍
梁小玲
陈锡和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heng Ruiyuan Zheng Guangzhou Biotechnology Co ltd
Henry Is Source Of Biological Science And Technology Co ltd Shanghai
Original Assignee
Hengrui Yuanzheng Shenzhen Biological Technology Co ltd
Syz Cell Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengrui Yuanzheng Shenzhen Biological Technology Co ltd, Syz Cell Therapy Co filed Critical Hengrui Yuanzheng Shenzhen Biological Technology Co ltd
Publication of CN113185602A publication Critical patent/CN113185602A/zh
Application granted granted Critical
Publication of CN113185602B publication Critical patent/CN113185602B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4208—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/4239—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
CN202110295872.5A 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法 Active CN113185602B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/082947 2018-04-13
PCT/CN2018/082947 WO2019196088A1 (en) 2018-04-13 2018-04-13 Methods of obtaining tumor-specific t cell receptors
CN201980025587.2A CN112534045A (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法
PCT/CN2019/082408 WO2019196924A1 (en) 2018-04-13 2019-04-12 Methods of obtaining tumor-specific t cell receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980025587.2A Division CN112534045A (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法

Publications (2)

Publication Number Publication Date
CN113185602A CN113185602A (zh) 2021-07-30
CN113185602B true CN113185602B (zh) 2023-03-10

Family

ID=68163041

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202110295872.5A Active CN113185602B (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法
CN201980025587.2A Pending CN112534045A (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法
CN202110295574.6A Active CN112979783B (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法
CN202310140638.4A Pending CN116003575A (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201980025587.2A Pending CN112534045A (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法
CN202110295574.6A Active CN112979783B (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法
CN202310140638.4A Pending CN116003575A (zh) 2018-04-13 2019-04-12 获得肿瘤特异性t细胞受体的方法

Country Status (6)

Country Link
US (6) US11390659B2 (cg-RX-API-DMAC7.html)
EP (1) EP3775168A4 (cg-RX-API-DMAC7.html)
JP (2) JP7549826B2 (cg-RX-API-DMAC7.html)
KR (1) KR102805266B1 (cg-RX-API-DMAC7.html)
CN (4) CN113185602B (cg-RX-API-DMAC7.html)
WO (2) WO2019196088A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
CN116298309B (zh) 2018-08-13 2024-04-02 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
MX2021012207A (es) 2019-04-05 2021-12-10 Rootpath Genomics Inc Composiciones y métodos para ensamblaje de genes del receptor de linfocitos t.
JP2022535006A (ja) * 2019-05-31 2022-08-04 モデルナティエックス インコーポレイテッド 増殖t細胞アッセイ
US20210040558A1 (en) * 2019-07-15 2021-02-11 Neogene Therapeutics B.V. Method to isolate tcr genes
EP4061487A4 (en) * 2019-11-19 2023-12-20 Rootpath Genomics, Inc. COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR
US12612444B2 (en) 2019-11-26 2026-04-28 University of Pittsburgh—of the Commonwealth System of Higher Education T cell receptors targeting mutations in RNA splicing factors
EP4100051A2 (en) * 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
CN111234005B (zh) * 2020-03-13 2022-11-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 氨苯砜药物超敏反应性t细胞受体及其用途
IL301543A (en) * 2020-09-24 2023-05-01 Medigene Immunotherapies Gmbh Prame specific t cell receptors and uses thereof
JP2024526836A (ja) * 2021-07-19 2024-07-19 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Fanci、rad51、およびpbk抗原を標的とするペプチドおよび操作されたt細胞受容体ならびに使用の方法
WO2023049733A2 (en) * 2021-09-21 2023-03-30 The University Of Chicago Methods and composition using patient-derived autologous neoantigens for treating cancer
CN116063511B (zh) * 2021-09-30 2023-10-03 北京可瑞生物科技有限公司 抗原结合蛋白及其应用
US20250025499A1 (en) * 2021-11-02 2025-01-23 Fred Hutchinson Cancer Center T cell immunotherapy for hematologic malignancies having an sf3b1 mutation
CN119677842A (zh) * 2022-03-17 2025-03-21 科士华(南京)生物技术有限公司 人工合成肿瘤浸润淋巴细胞
US20260166144A1 (en) * 2022-04-07 2026-06-18 Carsgen Life Sciences Co., Ltd. Chimeric polypeptide and use thereof
CN116063458A (zh) * 2022-04-27 2023-05-05 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
AU2023269389A1 (en) * 2022-05-10 2024-12-19 Geneos Therapeutics, Inc. Individualized cancer epitopes and methods of using the same
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用
EP4739702A1 (en) * 2023-07-07 2026-05-13 The University Of Hong Kong Convergent recombination-derived hepatocellular carcinoma-specific tcrs and applications thereof
CN117567595B (zh) * 2024-01-17 2024-05-14 恒瑞源正(广州)生物科技有限公司 Mage-a4特异性t细胞受体及其用途
CN120518771A (zh) * 2024-02-20 2025-08-22 上海信谱生物医药科技有限公司 一种识别kras突变的t细胞受体及其编码序列
WO2025193663A2 (en) * 2024-03-11 2025-09-18 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia
CN119613530B (zh) * 2024-12-13 2025-09-05 华中科技大学 一种靶向肝癌细胞甲胎蛋白抗原肽与hla-a24复合物的特异性tcr分子、tcr-t细胞及制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415827A (zh) * 2005-12-09 2009-04-22 阿哥斯医疗公司 产生抗原特异性效应t细胞的方法
CN107735492A (zh) * 2015-03-13 2018-02-23 深圳源正细胞医疗技术有限公司 使用活化t细胞治疗癌的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
CN1609197A (zh) * 2003-10-17 2005-04-27 上海普泛生物科技有限公司 一种用于发现肿瘤特异性抗原和肿瘤特异性抗原决定簇的高产率逆反免疫法
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2006249640C1 (en) * 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
EP2468763B1 (en) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
AU2008323853B8 (en) 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
DK2271767T3 (en) 2008-04-03 2016-08-29 Cb Biotechnologies Inc Amplikonredning-multiplex polymerase chain reaction for the amplification of multiple target
EP2258719A1 (en) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
EP3144673B1 (en) * 2010-05-06 2019-07-10 Adaptive Biotechnologies Corporation Monitoring lymphoid neoplasm status using clonotype profiles
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US9187534B2 (en) * 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
US9345770B2 (en) * 2011-11-16 2016-05-24 University of Pittsburgh—of the Commonwealth System of Higher Education Immunogenic tumor associated stromal cell antigen peptides and methods of their use
JP6309209B2 (ja) * 2013-05-31 2018-04-11 国立研究開発法人国立国際医療研究センター 血管平滑筋細胞の増殖を抑制する血管内皮細胞の検出方法
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
CN105452448B (zh) 2013-07-15 2020-07-28 美国卫生和人力服务部 制备抗人乳头瘤病毒抗原的t细胞的方法
SG11201702191YA (en) 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
CN104593325A (zh) * 2014-12-09 2015-05-06 深圳源正细胞医疗技术有限公司 诱导dc成熟并分泌高浓度促炎因子的方法
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
US20180171294A1 (en) 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
US20170319638A1 (en) * 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
CN109803674A (zh) * 2016-06-10 2019-05-24 Io生物技术公司 Calr和jak2疫苗组合物
US9642906B2 (en) * 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
CN106645677B (zh) * 2016-11-15 2019-08-09 恒瑞源正(上海)生物科技有限公司 体外检测肿瘤新生抗原特异性t细胞的方法、试剂盒以及肿瘤疫苗
MD3551221T2 (ro) * 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415827A (zh) * 2005-12-09 2009-04-22 阿哥斯医疗公司 产生抗原特异性效应t细胞的方法
CN107735492A (zh) * 2015-03-13 2018-02-23 深圳源正细胞医疗技术有限公司 使用活化t细胞治疗癌的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients;T H Ottenhoff等;《JOURNAL OF EXPERIMENTAL MEDICINE》;19861201;第164卷(第4期);第1923-1939页 *
Regulator of G-protein signaling 5 [Cricetulus griseus];XU,XU.等;《GENBANK DATABASE》;20150314;ORIGIN *
regulator of G-protein signaling 5, isoform CRA_b [Rattus norvegicus];Mural,R.J.等;《GENBANK DATABASE》;20160726;ORIGIN *

Also Published As

Publication number Publication date
CN112979783B (zh) 2023-02-17
TW202012619A (zh) 2020-04-01
WO2019196924A1 (en) 2019-10-17
US20220402999A1 (en) 2022-12-22
US20240052010A1 (en) 2024-02-15
CN113185602A (zh) 2021-07-30
US20230212253A1 (en) 2023-07-06
US20230023834A1 (en) 2023-01-26
KR20210003794A (ko) 2021-01-12
US20220403000A1 (en) 2022-12-22
CN112534045A (zh) 2021-03-19
JP2024069663A (ja) 2024-05-21
US11390659B2 (en) 2022-07-19
US20210198341A1 (en) 2021-07-01
US12358967B2 (en) 2025-07-15
KR102805266B1 (ko) 2025-05-08
CN116003575A (zh) 2023-04-25
EP3775168A4 (en) 2022-04-20
JP7549826B2 (ja) 2024-09-12
JP2021520849A (ja) 2021-08-26
WO2019196088A1 (en) 2019-10-17
EP3775168A1 (en) 2021-02-17
CN112979783A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
CN112979783B (zh) 获得肿瘤特异性t细胞受体的方法
KR102698909B1 (ko) 활성화된 t 세포를 사용하는 암 치료 방법
US20220235324A1 (en) Multiple antigen specific cell therapy methods
US11471519B2 (en) Methods of cancer treatment using tumor antigen-specific T cells
Wang et al. Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles
CN117957012A (zh) 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230907

Address after: 200120 Building 24, No. 199 Guangfulin East Road, Songjiang District, Shanghai

Patentee after: Henry is the source of biological science and Technology Co.,Ltd. (Shanghai)

Patentee after: HENGRUI YUANZHENG (SHENZHEN) BIOLOGICAL TECHNOLOGY CO.,LTD.

Address before: 518057 15th floor, South Block, No.1 songpingshan Road, gaoxinyuan North District, Nanshan District, Shenzhen City, Guangdong Province

Patentee before: SYZ CELL THERAPY CO.

Patentee before: HENGRUI YUANZHENG (SHENZHEN) BIOLOGICAL TECHNOLOGY CO.,LTD.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231226

Address after: Building 24, No. 199 Guangfulin East Road, Songjiang District, Shanghai, 201600

Patentee after: Henry is the source of biological science and Technology Co.,Ltd. (Shanghai)

Patentee after: Heng Ruiyuan Zheng (Guangzhou) Biotechnology Co.,Ltd.

Address before: 200120 Building 24, No. 199 Guangfulin East Road, Songjiang District, Shanghai

Patentee before: Henry is the source of biological science and Technology Co.,Ltd. (Shanghai)

Patentee before: HENGRUI YUANZHENG (SHENZHEN) BIOLOGICAL TECHNOLOGY CO.,LTD.